# The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis

> **NCT03129126** · PHASE2 · COMPLETED · sponsor: **Lipella Pharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Hemorrhagic Cystitis

## Interventions

- **DRUG:** LP-10

## Key facts

- **NCT ID:** NCT03129126
- **Lead sponsor:** Lipella Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-09-29
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03129126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03129126, "The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03129126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*